685 related articles for article (PubMed ID: 34437922)
1. JAK inhibitors in the treatment of atopic dermatitis.
Chovatiya R; Paller AS
J Allergy Clin Immunol; 2021 Oct; 148(4):927-940. PubMed ID: 34437922
[TBL] [Abstract][Full Text] [Related]
2. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors.
Nakashima C; Yanagihara S; Otsuka A
Allergol Int; 2022 Jan; 71(1):40-46. PubMed ID: 34815171
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
[TBL] [Abstract][Full Text] [Related]
4. Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis.
Wood H; Chandler A; Nezamololama N; Papp K; Gooderham MJ
Int J Dermatol; 2022 Jun; 61(6):746-754. PubMed ID: 34423443
[TBL] [Abstract][Full Text] [Related]
5. The suitability of treating atopic dermatitis with Janus kinase inhibitors.
Narla S; Silverberg JI
Expert Rev Clin Immunol; 2022 May; 18(5):439-459. PubMed ID: 35377276
[TBL] [Abstract][Full Text] [Related]
6. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
[TBL] [Abstract][Full Text] [Related]
7. Janus kinase inhibitors for the therapy of atopic dermatitis.
Traidl S; Freimooser S; Werfel T
Allergol Select; 2021; 5():293-304. PubMed ID: 34532638
[TBL] [Abstract][Full Text] [Related]
8. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis.
Calabrese L; Chiricozzi A; De Simone C; Fossati B; D'Amore A; Peris K
Expert Opin Drug Metab Toxicol; 2022 May; 18(5):347-355. PubMed ID: 35796377
[TBL] [Abstract][Full Text] [Related]
10. New molecules for atopic dermatitis treatment beyond biological therapy.
Freitas E; Torres T
Curr Opin Allergy Clin Immunol; 2023 Jun; 23(3):210-215. PubMed ID: 37185825
[TBL] [Abstract][Full Text] [Related]
11. Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib.
Ferreira S; Guttman-Yassky E; Torres T
Am J Clin Dermatol; 2020 Dec; 21(6):783-798. PubMed ID: 32776305
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib cream for the short-term treatment of mild-moderate atopic dermatitis.
Krajewski PK; Szepietowski JC
Expert Rev Clin Immunol; 2023 Apr; 19(4):349-356. PubMed ID: 36542765
[TBL] [Abstract][Full Text] [Related]
13. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.
Nakagawa H; Nemoto O; Igarashi A; Saeki H; Kaino H; Nagata T
J Am Acad Dermatol; 2020 Apr; 82(4):823-831. PubMed ID: 32029304
[TBL] [Abstract][Full Text] [Related]
14. JAK/STAT inhibitors for the treatment of atopic dermatitis.
Rodrigues MA; Torres T
J Dermatolog Treat; 2020 Feb; 31(1):33-40. PubMed ID: 30703333
[No Abstract] [Full Text] [Related]
15. Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis.
Hoy SM
Am J Clin Dermatol; 2023 Jan; 24(1):143-151. PubMed ID: 36538235
[TBL] [Abstract][Full Text] [Related]
16. English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors in the treatments of atopic dermatitis.
Saeki H; Akiyama M; Abe M; Igarashi A; Imafuku S; Ohya Y; Katoh N; Kameda H; Kabashima K; Tsunemi Y; Hide M; Ohtsuki M;
J Dermatol; 2023 Jan; 50(1):e1-e19. PubMed ID: 36412059
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of Janus kinase inhibitors in patients with atopic dermatitis: A systematic review and network meta-analysis.
Zhang L; Wang L; Jiang X
Dermatol Ther; 2021 Sep; 34(5):e15098. PubMed ID: 34392600
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis.
Wan H; Jia H; Xia T; Zhang D
Dermatol Ther; 2022 Sep; 35(9):e15636. PubMed ID: 35703351
[TBL] [Abstract][Full Text] [Related]
19. Janus Kinase Inhibitors in Atopic Dermatitis: New Perspectives.
Munera-Campos M; Carrascosa JM
Actas Dermosifiliogr; 2023 Sep; 114(8):680-707. PubMed ID: 37105270
[TBL] [Abstract][Full Text] [Related]
20. Abrocitinib for the treatment of atopic dermatitis.
Crowley EL; Nezamololama N; Papp K; Gooderham MJ
Expert Rev Clin Immunol; 2020 Oct; 16(10):955-962. PubMed ID: 32969750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]